Jul 2026· Open Access Government· Vol 51, pp. 194-195· 0 citations
TL;DR
It is argued that Canada needs to move toward a genomics-informed learning health system for rare disease (RD); one in which diagnosis, care, discovery, and patient outcomes are connected in a continuous cycle of learning.
Abstract
With sustained investment and a national vision, Canada has the potential to create a more integrated and effective system for managing rare diseases. In the first article in this series, we argued that Canada needs to move toward a genomics-informed learning health system for rare disease (RD); one in which diagnosis, care, discovery, and patient outcomes are connected in a continuous cycle of learning. Canada possesses many of the foundational components. Across the country, clinicians, clinician-scientists, and researchers have developed innovative programs and infrastructure. However, these initiatives are too often supported through short-term funding cycles and limited budgets that are insufficient to sustain, scale, or integrate successful programs over the long term. At the same time, funding structures often prioritize new initiatives over the expansion and coordination of existing ones, contributing to duplication of effort and a tendency to reinvent the wheel.
It is argued that the value of genomic medicine for rare disease should be assessed beyond diagnostic yield alone and across individual, clinical and societal levels.
R. Horn, Sarah L. Wynn, S. Houge· Journal of Genetic Counselin...· 0 citations
Rare diseases affect over 400 million people worldwide and present a major opportunity for health system reform. Primary mitochondrial disease comprises progressive, genetically heterogeneous disorders caused by pathogenic variants in mitochondrial or nuclear DNA, with an estimated prevalence of 1 in 4300 and likely un...
Amanda Temby, R. Stefanetti, Lyndsey Butterworth et al.· BMJ Innovations· 0 citations
Background: Cardiovascular disease remains the leading cause of death worldwide, and congenital heart disease affects just under one percent of live births. Inequality stems from lack of access to timely diagnosis and life-saving intervention, particularly across low and middle-income countries where specialists, infra...
Ramesh Dharmaraj, A. Kalangos, S. Setty· Journal of Humanitarian Card...· 0 citations
In 2005, the National Institutes of Health (NIH) announced the Clinical and Translational Science Award (CTSA) program – an institution-based grant intended to re-engineer the clinical research enterprise, speeding the time from pre-clinical discovery to the development of therapies to improve human health. As universi...
A framework for evaluating the translational impact of the Gabriella Miller Kids First Program enables systematic assessment of how research investments contribute to clinically actionable knowledge and translational impact, providing a model for evaluating future precision medicine and pediatric oncology research init...
Advances in high-throughput sequencing technologies have transformed human genomics, enabling large-scale initiatives to characterise genome structure, function, and population diversity. Following foundational international projects such as the Human Genome Project, HapMap, and the 1000 Genomes Project, many countri...
Špela Gruden, Lucija Raspor dall'Olio, J. Hancock et al.· Human Genomics· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.